-+ 0.00%
-+ 0.00%
-+ 0.00%

Pfizer Signs Exclusive Licensing Agreement With Starna Therapeutics To Commercialize Three Pre-IND In Vivo Chimeric Antigen Receptor T-Cell Programs Outside Of China For $330M Up Front And Up To $2.3B In Milestones

Benzinga·11/18/2026 11:49:05
Listen to the news

Deal Terms and Financial Details

Starna will receive an upfront payment of $330 million.
Starna is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products.
Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in the United States.
Pfizer will have sole and exclusive control over commercialization outside of Greater China for all products.
Pfizer holds options to expand its territory to include Greater China.
Advancing Promising Science for Patients

Today’s agreement broadens Pfizer’s Inflammation & Immunology pipeline and enables Pfizer to deploy its extensive scientific expertise in RNA delivery and specialization in immunology research, clinical development and commercialization to a promising, next-generation approach in cell therapy. Starna’s innovative technology provides future opportunities to design potentially transformative autoimmune and cancer treatments.